Comparing the current results to its competitors, Artelo Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.97 %, recorded in the same quarter.
Artelo Biosciences Inc , slower than the average decrease reported by the company's competitors of -83.08 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -83.08 %
Artelo Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industry, which is characterized by rapid technological advancements and intense competition. It aims to compete by developing therapeutics that demonstrate clinical utility, acceptable safety profiles, and address indications with unmet medical needs. Competitors include Novartis International AG, Helsinn Therapeutics (U.S.), Inc., NGM Biopharmaceuticals Inc., Jazz Pharmaceuticals Inc., Skye Bioscience, Longboard Pharmaceuticals, and Pfizer Inc. These competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. The company's commercial opportunities may be limited if competitors develop safer, more effective, more convenient, or less expensive medicines or obtain regulatory approvals more rapidly.
September 3, 2025
: This article examines the recent developments surrounding Artelo Biosciences, Inc., focusing on the company’s encouraging interim Phase 2 results for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS) utilizing ART27.13. Despite these promising clinical outcomes, Artelo s stock performance has lagged behind market expectations and competitors, raising questions about investor confidence and market dynamics. This article outlines the clinical results and discusses potential implications for the company s future and its interactions with pharmaceutical partners. Artelo Biosciences, Inc. is a biotechnology company focused on developing therapies for patients suffering from serious diseases associa...
July 7, 2025
The treatment of mood and anxiety disorders continues to present significant challenges, prompting ongoing research into novel therapeutic pathways. Traditional pharmacologic approaches, primarily selective serotonin reuptake inhibitors (SSRIs), have finite efficacy and are often accompanied by adverse effects that can compromise patient adherence. Recent advancements in lipid signaling pathway modulation, particularly through the development of Fatty Acid Binding Protein (FABP) inhibitors, provide a compelling frontier in the pharmacotherapy of stress-induced depression and anxiety disorders. This article synthesizes recent findings from Artelo Biosciences, shedding light on the promise of their experimenta...
November 13, 2024
Cutting-Edge Advances in Pain and Anxiety Management: Artelo Biosciences Groundbreaking Discoveries in Non-Opioid Treatments Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make significant strides in the development of novel non-opioid treatment options, showcasing their unwavering commitment to addressing some of the most prevalent challenges in modern medicine: pain management and anxiety disorders. At prestigious scientific symposia, Artelo has presented compelling preclinical data that highlight both their innovative approaches and promising product candidates, ART26.12 and ART12.11.At the recent 13th Annual Musculoskeletal Repair and Regeneration Symposium, Artelo unv...
July 15, 2024
Artelo Biosciences Receives FDA Clearance for ART26.12: A Promising Breakthrough in Painful Neuropathies Treatment Addressing the Unmet Need in Painful NeuropathiesPainful neuropathies, such as chemotherapy-induced peripheral neuropathy (CIPN), pose significant challenges to patients and healthcare providers alike. These conditions, characterized by intense pain, numbness, and tingling sensations, can greatly impact patients quality of life and impede their ability to perform daily activities. Unfortunately, despite the high prevalence of neuropathic pain, there is a dearth of FDA-approved treatments specifically targeting CIPN.Artelo Biosciences, a leading biopharmaceutical company focused on developing in...
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
Enveric Biosciences Inc's business model centers around the development and commercialization of innovative cannabinoid medicines and therapies to address various medical conditions, primarily focusing on cancer-related symptoms and improving patient outcomes. The company aims to leverage its expertise in the pharmaceutical industry to advance its pipeline, obtain regulatory approvals, and establish strategic partnerships for the distribution and sale of its products.
BioXcel Therapeutics Inc. is a biopharmaceutical company that operates using an innovative business model. They utilize artificial intelligence (AI) and big data analytics to identify and develop novel therapies for targeted diseases with unmet medical needs. This approach allows them to leverage data-driven insights to expedite drug discovery and development, potentially increasing the efficiency and success rate of their drug candidates.
Sources:
Artelo Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Artelo Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
